National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®), in combination with axitinib (Inlyta®), is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults.

NCPE Assessment Process Complete
Rapid review commissioned 29/07/2019
Rapid review completed 23/08/2019
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with axitinib compared with the current standard of care.